Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats
autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and …

Success in developing novel therapies to recommence self-tolerance in autoimmunity
depends on the induction of T regulatory (Tr) cells. Here, we report that rapamycin combined …

OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft
rejection in humans, which is considered permissive for tolerance induction. Rapamycin …

The effect of the immunosuppressive agent rapamycin (RAPA) was assessed in the non‐
obese diabetic (NOD) mouse which is an autoimmune model of IDDM. RAPA was prepared …

Sirolimus is an immunosuppressant that inhibits interleukin (IL)-2 signaling of T-cell
proliferation but not IL-2-induced T-cell apoptosis. Therefore, we hypothesized that …

Background IL-6 receptor (IL-6R) signaling drives development of T cell populations
important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with …

Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of insulin producing
beta cells. Regulatory T cells (Tregs) have been shown to be defective in this setting …

Islet transplantation is a cure for type 1 diabetes, but its potential is limited by the need for
constant immunosuppression. One solution to this problem is the induction of transplantation …

Regulatory T cells (T reg cells) play a major role in controlling the pathogenic autoimmune
process in type 1 diabetes (T1D). Interleukin 2 (IL-2), a cytokine which promotes T reg cell …

OBJECTIVE—Mammalian target of rapamycin (mTOR) and its downstream target S6 kinase
1 (S6K1) mediate nutrient-induced insulin resistance by downregulating insulin receptor …